Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recruiting × Alpelisib × Clear all

Phase

Phase 2 4 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1

Interventions

Cisplatin 18 pembrolizumab 16 Gemcitabine 12 Paclitaxel 10 Carboplatin 10 Drug Therapy 9 Dexamethasone 8 venetoclax 7 Magnetic Resonance Spectroscopy 7 Docetaxel 7 Bevacizumab 7 atezolizumab 6 Nivolumab 6 Cyclophosphamide 6 durvalumab 5 Specimen Handling 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Methotrexate 5 Cytarabine 5 Taxes 4 Standard of Care 4 Injections 4 Fluorouracil 4 Daunorubicin 4 Capecitabine 4 Azacitidine 4 130-nm albumin-bound paclitaxel 4 spartalizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡